Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common.

In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury in the course of COVID 19 disease.

Inclusion Criteria:

• Patients with amylase and lipase levels measured during covid-19 disease with or without pneumonia

Exclusion Criteria:

• Patients with pregnancy
• Patients whose amylase and lipase levels were not measured during covid 19 disease
• Patients with known solid organ malignacy
• Patients with known hematologic malignacy

Patients who develop amylase and lipase elevation during the course of COVID 19 will be considered in the pancreatic injury group. Those who do not develop will be counted as the control group.